INSUFFICIENT IN-SCOPE MATERIAL
Finding: The Jul 13–15 window contains zero actionable biotech-AI intersection signals.
Why:
- @crypto_condom's $BB tweets (BlackBerry QNX, physical AI RTOS) are off-scope—BlackBerry is embedded systems/enterprise software, not biotech or AI-designed therapeutics.
- @biotech2k1's positioning churn ($TE solar, fintech rotation, space-stock skepticism) is off-scope—no biotech-AI activity.
- @adamfeuerstein's live calls are already covered: Avere ($NXTC) reverse merger and $BIIB tau readout (Diranersen) were the substance of the Jul 14 dispatch sent yesterday. His Jul 15 Sac-TMT/MRK note ($MRK Kelun oncology ADC) sits outside biotech-AI.
- @biologyaidaily's technical deep-dives (IgGM2, FlexRibbon, ESM3 geometry, ARSENAL DNA models) are published benchmarks—no market catalyst, no conviction repositioning, no clinical inflection.
- @maverickny's Celcuity gedatolisib approval (breast cancer PI3K/mTOR) is tangential: clinical win in cancer, not AI-designed or AI-gated; no source conviction stated.
- Wainua collapse hardening developability-gating (Jul 10)
- Avere execution pivot away from protein design speculation (Jul 14)
- Rotation into proven manufacturing/formulation teams
RECOMMENDATION: SKIP DISPATCH
Resume when:
- AAIC26 (ongoing) produces biotech-AI-specific readouts (AI-designed drug efficacy, BBB penetration signals tied to AI screening)
- Live clinical trial readout in an AI-designed therapeutic (not generic biotech wins)
- Platform adoption or pricing inflection in protein-design tools ($BBIO pipeline depth, $ALNY next-gen platform)
- M&A or public offering in a biotech-AI play